Intellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 2,641 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $17.09 on Tuesday. The business has a fifty day moving average of $14.17 and a 200-day moving average of $13.13. Intellia Therapeutics, Inc. has a twelve month low of $7.95 and a twelve month high of $28.25. The firm has a market cap of $2.39 billion, a PE ratio of -4.84 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The firm had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter in the prior year, the firm earned ($1.10) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -3.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NTLA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st. Truist Financial upgraded Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $49.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. New Street Research set a $25.00 price objective on Intellia Therapeutics in a research report on Monday, June 15th. Finally, Leerink Partners set a $35.00 price objective on Intellia Therapeutics in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $20.46.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new stake in shares of Intellia Therapeutics in the first quarter valued at approximately $404,000. Avidity Partners Management LP bought a new position in Intellia Therapeutics during the first quarter worth $962,000. Wellington Grp LLC increased its holdings in shares of Intellia Therapeutics by 50.9% in the first quarter. Wellington Grp LLC now owns 46,297 shares of the company’s stock valued at $594,000 after purchasing an additional 15,620 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Intellia Therapeutics by 11.2% during the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after buying an additional 139,325 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in Intellia Therapeutics in the 1st quarter valued at about $250,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.